Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 4:57 pm Sale |
2023-12-31 | 13G | Catcha Investment Corp CHAA |
Citadel Advisors LLC | 6,410 0.300% |
-2,198,479 (-99.71%) |
Filing History |
| 2024-02-14 4:57 pm Sale |
2023-12-31 | 13G | Project Energy Reimagined Acquisition Corp. PEGR |
Citadel Advisors LLC | 172,489 1.000% |
-2,043,562 (-92.22%) |
Filing History |
| 2024-02-14 4:57 pm Sale |
2023-12-31 | 13G | Spruce Biosciences, Inc. SPRB |
Citadel Advisors LLC | 108,240 0.300% |
-1,639,151 (-93.81%) |
Filing History |
| 2024-02-14 4:57 pm Purchase |
2023-12-31 | 13G | Ventyx Biosciences, Inc. VTYX |
Citadel Advisors LLC | 4,279,553 7.300% |
490,758 (+12.95%) |
Filing History |
| 2024-02-14 4:57 pm Sale |
2023-12-31 | 13G | Vera Therapeutics, Inc. VERA |
Citadel Advisors LLC | 43,447 0.100% |
-1,948,106 (-97.82%) |
Filing History |
| 2024-02-14 4:57 pm Sale |
2023-12-31 | 13G | Vigil Neuroscience, Inc. VIGL |
Citadel Advisors LLC | 2,161,902 6.000% |
-2,014 (-0.09%) |
Filing History |
| 2024-02-14 4:57 pm Sale |
2023-12-31 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO |
Citadel Advisors LLC | 2,084,267 7.800% |
-8,221 (-0.39%) |
Filing History |
| 2024-02-14 4:57 pm Purchase |
2023-12-31 | 13G | AN2 Therapeutics, Inc. ANTX |
Citadel Advisors LLC | 1,556,842 5.200% |
219,849 (+16.44%) |
Filing History |
| 2024-02-14 4:57 pm Sale |
2023-12-31 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL |
Citadel Advisors LLC | 3,738,482 5.300% |
-101,347 (-2.64%) |
Filing History |
| 2024-02-14 4:57 pm Sale |
2023-12-31 | 13G | VYNE Therapeutics Inc. VYNE |
Citadel Advisors LLC | 1,181,144 8.500% |
-23 (-0.00%) |
Filing History |
| 2024-02-14 4:57 pm Sale |
2023-12-31 | 13G | Korro Bio, Inc. KRRO |
Citadel Advisors LLC | 529,251 6.600% |
-16,967 (-3.11%) |
Filing History |
| 2024-02-14 4:57 pm Purchase |
2023-12-31 | 13G | Aura Biosciences, Inc. AURA |
Citadel Advisors LLC | 3,631,494 7.400% |
894,441 (+32.68%) |
Filing History |
| 2024-02-14 4:57 pm Sale |
2023-12-31 | 13G | Bolt Biotherapeutics, Inc. BOLT |
Citadel Advisors LLC | 2,458,958 6.500% |
-293,237 (-10.65%) |
Filing History |
| 2024-02-14 4:57 pm Purchase |
2023-12-31 | 13G | Dyne Therapeutics, Inc. DYN |
Citadel Advisors LLC | 3,072,587 5.000% |
91,263 (+3.06%) |
Filing History |
| 2024-02-14 4:57 pm Sale |
2023-12-31 | 13G | Ikena Oncology, Inc. IKNA |
Citadel Advisors LLC | 178,177 0.400% |
-1,976,957 (-91.73%) |
Filing History |
| 2024-02-14 4:57 pm Sale |
2023-12-31 | 13G | Immuneering Corporation IMRX |
Citadel Advisors LLC | 2,078,092 7.100% |
-63,405 (-2.96%) |
Filing History |
| 2024-02-14 4:57 pm Sale |
2023-12-31 | 13G | MoonLake Immunotherapeutics MLTX |
Citadel Advisors LLC | 2,034,260 3.400% |
-851,832 (-29.52%) |
Filing History |
| 2024-02-14 4:57 pm Purchase |
2023-12-31 | 13G | Acrivon Therapeutics, Inc. Common Stock ACRV |
Citadel Advisors LLC | 1,649,664 7.400% |
15,515 (+0.95%) |
Filing History |
| 2024-02-14 4:57 pm Sale |
2023-12-31 | 13G | Northern Star Investment Corp. II NSTB |
Citadel Advisors LLC | 806 0.000% |
-50,128 (-98.42%) |
Filing History |
| 2024-02-14 4:57 pm Purchase |
2023-12-31 | 13G | Tourmaline Bio, Inc. TRML |
Citadel Advisors LLC | 2,265 0.000% |
2,265 (New Position) |
Filing History |